The identification of key oncogenic driver alterations in NSCLC has led to the development of tailored treatments. ROS1 rearrangements occur in 1% to 2% of NSCLC.1 Dysregulation of MNNG HOS Transforming gene (MET) signaling through MET exon 14 skipping mutations or MET amplification has been reported in 3% to 4% and 2% to 5% of adenocarcinomas, respectively.2 To our knowledge, co-alteration of c-MET and ROS1 or ALK tyrosine kinase receptor gene (ALK) have not been described yet and the optimal management of this clinical condition is unknown.
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins
Rihawi K;Fiorentino M;SALVAGNI, SANDRO;Brocchi S;Ardizzoni A
2018
Abstract
The identification of key oncogenic driver alterations in NSCLC has led to the development of tailored treatments. ROS1 rearrangements occur in 1% to 2% of NSCLC.1 Dysregulation of MNNG HOS Transforming gene (MET) signaling through MET exon 14 skipping mutations or MET amplification has been reported in 3% to 4% and 2% to 5% of adenocarcinomas, respectively.2 To our knowledge, co-alteration of c-MET and ROS1 or ALK tyrosine kinase receptor gene (ALK) have not been described yet and the optimal management of this clinical condition is unknown.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.